Skip to main content
Caplight Logo









Salus BioMed

Salus BioMed

Private
ShenzhenHealthcare & Life Scienceshttps://www.salus-bio.com/

Last Round

Series B

Oct 10, 2025

Total Funding Raised

$20.92M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Salus BioMed is a life sciences company that provides a DNA sequencing platform and develops high-definition spatial transcriptomics to measure gene activity, aiding in the diagnosis and treatment of diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Medical Devices, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales, Data as a Service

AI Layer

Non-AI

Keywords

genetic sequencingnext-generation sequencingNGSspatial transcriptomicssequencing-by-synthesisSBSclinical diagnosticsprecision oncologygenomicsbenchtop sequencersequencing reagentsbioinformaticsrazor and bladesbiotech equipmentlab automation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Salus BioMed Comparables

Compare Salus BioMed with similar companies based on industry and business-model similarity.

Salus BioMed comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
GeneMind Biosciences Co., Ltd.
88%
Qitan Tech
84%
Axbio
78%

Salus BioMed Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BOct 10, 2025
Series A ExtensionMay 14, 2025
Series ADec 1, 2023
SeedOct 18, 2022
AngelOct 1, 2021

Salus BioMed Investors

Notable investors and investment history

Salus BioMed investors
InvestorRounds
BioTrack CapitalSeries A
ZhenFundAngel
苏州敦行投资管理有限公司Series A
Qianhai Ark Asset ManagementSeries A
Shenzhen Capital GroupSeries A Extension, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors grew 849% MoM, from 45 to 427.

  • Aug 1, 2026

    Grew 25% QoQ, from 20 to 25 employees.

Salus BioMed Filings

Explore SEC and related filing metadata, where available.

Salus BioMed filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Salus BioMed's valuation, stock price, and market status.

Is Salus BioMed a public or private company?

Salus BioMed is a private company.

What is the current stock price of Salus BioMed?

Salus BioMed is a private company with no public stock price. No recent secondary market data is available.

How much is Salus BioMed worth (valuation)?

Valuation information for Salus BioMed is not publicly available.

Can I buy Salus BioMed stock?

Salus BioMed shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Salus BioMed's last funding round?

Salus BioMed's most recent funding round was Series A Extension on May 14, 2025.

Who are the main investors in Salus BioMed?

Key investors in Salus BioMed include BioTrack Capital, Qianhai Ark Asset Management, Shenzhen Capital Group.

Will Salus BioMed IPO soon?

No public IPO plans have been announced for Salus BioMed.

How can I track Salus BioMed secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Salus BioMed's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersShenzhen
Employee Range22
Year Founded2020
Last FundingOct 10, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?